CJC-1295 (DAC)
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
At a glance
- Peptide
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- 1000 mcg per Peptide Dosing Protocols. All 2 sources
- 10 mg in 3 mL
How much to draw
Full calculator →Opened on 1000 mcg, the figure Peptide Dosing Protocols reports for CJC-1295 (DAC), and a 10 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CJC-1295 (DAC) or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 1,000 mcg once weekly · Low: 500-1,000 mcg once weekly · High: 2,000 mcg once weekly or 1 mg twice weekly | once weekly8-12 weeks · 8-12 weeks on, 4-6 weeks off | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: 6-8 days. Common research-planning ranges land between 1-2 mg subcutaneously once weekly. |
| DAC version referenced at 2-3 mg per dose; extended half-life supports infrequent dosing. Bedtime administration cited to align with sleep-phase GH release. | 1-2x weekly · Optionally before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks | subcutaneous | Peptide Therapy Reference TextWhat it saysHideAug 2026), secondary reference; provider confirmation required. |
- once weekly8-12 weeks · 8-12 weeks on, 4-6 weeks off
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
Half-life: 6-8 days. Common research-planning ranges land between 1-2 mg subcutaneously once weekly.
- 1-2x weekly · Optionally before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks
- subcutaneous
- Peptide Therapy Reference Text
What it saysHide
Aug 2026), secondary reference; provider confirmation required.
- reconstitute lyophilized powder with bacteriostatic water before use
We have not published an audit on CJC-1295 (DAC). Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Sticking to albumin shields the peptide from being broken down, so one injection keeps signalling the pituitary gland for roughly 6-8 days. Researchers describe it as a GHRH analog that lifts growth hormone and then IGF-1, insulin-like growth factor 1. Phase 1 data reported growth hormone up 2-10 fold for 6 or more days and IGF-1 up 1.5-3 fold for 9-11 days after a single dose. As of June 2026 it is not FDA-approved, and there is no long-term controlled human safety data beyond the 2006 program.
CJC-1295 with DAC binds to circulating albumin, which shields it from breakdown and extends its half-life to about 6-8 days, allowing for sustained signaling to the pituitary gland to release growth hormone. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: Phase 1 reports list injection-site pain, redness, itching, lumps and swelling, brief flushing or warmth, headache, nausea, water retention, and numbness or tingling in the hands and feet. Those cohorts recorded no serious adverse events and no one stopped because of side effects, and the lower 30-60 mcg/kg range was described as better tolerated than higher ones.
Not ruled out: a Phase 2 trial in HIV lipodystrophy (NCT00267527) was halted in 2006 after one participant died of a heart attack, which the attending doctor attributed to existing coronary disease rather than the drug. Because the peptide stays active for 6-8 days, any effect can last days instead of clearing in minutes.
Who should avoid it
People with active or recent cancer: raised growth hormone and IGF-1 are generally avoided in cancer settings.
People with significant heart disease: the Phase 2 trial that ended development included a participant death attributed to pre-existing coronary disease.
People with diabetes or pre-diabetes: raised growth hormone can affect insulin sensitivity.
People who are pregnant or breastfeeding: there is no human safety data in these groups.
People with a known peptide allergy: listed as a caution in the reference library, with no reason given.
Anyone without a qualified clinician involved: effects can persist for days, since the peptide stays active for 6-8 days.
What gets monitored
IGF-1 (baseline, mid-cycle, and end of cycle), fasting glucose, HbA1c, blood pressure, and resting heart rate during cycles. (reported by Peptide Dosing Protocols)
Common questions
What dose of CJC-1295 with DAC is reported in research planning?
Reported amounts and schedules for CJC-1295 (DAC) differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What is CJC-1295 with DAC's half-life?
Its estimated half-life is about 5.8-8.1 days. That is why a single injection keeps signalling the pituitary for close to a week.
What results were reported in CJC-1295 with DAC trials?
Phase 1 data reported growth hormone rising roughly 2-10 fold and IGF-1 rising 1.5-3 fold after a single dose. These were early-phase pharmacokinetic findings, not proof of a clinical benefit.
How is CJC-1295 with DAC reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Is CJC-1295 with DAC FDA-approved?
No. As of June 2026 it is not FDA-approved, and there is no active approval pathway after development was discontinued in 2006.
What are the most common side effects?
The effects reported most often are injection-site reactions, flushing, headache, stomach symptoms such as nausea, and water retention. They were more frequent in the higher-dose groups.
How does CJC-1295 with DAC compare to CJC-1295 without DAC?
Activity at the receptor is essentially the same for both. The DAC version differs by lasting 6-8 days instead of minutes.
What vial size does the reference assume?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.